IsoRay, Inc. (DE) (ISR): Price and Financial Metrics


IsoRay, Inc. (DE) (ISR): $1.40

-0.06 (-4.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ISR Stock Summary

  • ISR's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 393.11 -- higher than 90.09% of US-listed equities with positive expected earnings growth.
  • With a price/sales ratio of 20.82, Isoray Inc has a higher such ratio than 90.03% of stocks in our set.
  • The volatility of Isoray Inc's share price is greater than that of 94.89% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Isoray Inc are IRIX, VAPO, OXFD, ITI, and LNN.
  • Visit ISR's SEC page to see the company's official filings. To visit the company's web site, go to www.isoray.com.

ISR Stock Price Chart Interactive Chart >

Price chart for ISR

ISR Price/Volume Stats

Current price $1.40 52-week high $2.81
Prev. close $1.46 52-week low $0.35
Day low $1.31 Volume 6,630,600
Day high $1.48 Avg. volume 22,851,752
50-day MA $1.40 Dividend yield N/A
200-day MA $0.79 Market Cap 197.68M

IsoRay, Inc. (DE) (ISR) Company Bio


Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.


ISR Latest News Stream


Event/Time News Detail
Loading, please wait...

ISR Latest Social Stream


Loading social stream, please wait...

View Full ISR Social Stream

Latest ISR News From Around the Web

Below are the latest news stories about Isoray Inc that investors may wish to consider to help them evaluate ISR as an investment opportunity.

Here's Why We're Not At All Concerned With Isoray's (NYSEMKT:ISR) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | February 21, 2021

IsoRay Is Branching Out

IsoRay (ISR) is a company providing brachytherapy, a therapy that uses the radiation of little seeds implanted close to tumors in order to deliver targeted ongoing radiation therapy. IsoRay has unique seeds based on Cesium-131 which are particularly suited to this. Source: IR presentation January 2021 Here are the advantages...

Shareholders Unite on Seeking Alpha | February 17, 2021

ROCE Insights For IsoRay

During Q2, IsoRay's (AMEX:ISR) reported sales totaled $2.36 million. Despite a 21.29% in earnings, the company posted a loss of $866.00 thousand. In Q1, …

Benzinga | February 17, 2021

IsoRay, Inc. (ISR) CEO Lori Woods on Q2 2021 Results - Earnings Call Transcript

IsoRay, Inc. (ISR) Q2 2021 Earnings Conference Call February 09, 2021, 04:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Jonathan Hunt - CFO Conference Call Participants Mike Ott - Oppenheimer Frank Takkinen - Lake Street Presentation Operator Greetings, welcome to the Isoray's Second Quarter Fiscal...

SA Transcripts on Seeking Alpha | February 10, 2021

Isoray Announces Second Quarter Fiscal 2021 Financial Results

Revenue Increased 7% Year-Over-YearNon-Prostate Brachytherapy Revenue Increased 92% Year-Over-Year RICHLAND, Wash., Feb. 09, 2021 (GLOBE NEWSWIRE) --…

GlobeNewswire | February 9, 2021

Read More 'ISR' Stories Here

ISR Price Returns

1-mo -19.08%
3-mo 281.06%
6-mo 113.02%
1-year 90.48%
3-year 233.33%
5-year 70.73%
YTD 211.11%
2020 -27.93%
2019 108.13%
2018 -24.81%
2017 -31.21%
2016 -38.30%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8146 seconds.